1. The Implementation of Protocol-Based Utilization of Neuromuscular Blocking Agent Using Clinical Variables in Acute Respiratory Distress Syndrome Patients
- Author
-
Sarah Hadique, MD, Varun Badami, MD, Michael Forte, MD, Nicole Kovacic, PharmD, BCCCP, Amna Umer, PhD, Amanda Shigle, PharmD, Jordan Gardo, BSN, RN, CCRN, and Rahul Sangani, MD
- Subjects
Medical emergencies. Critical care. Intensive care. First aid ,RC86-88.9 - Abstract
Objectives:. The recent conflicting data on the mortality benefit of neuromuscular blocking agents in acute respiratory distress syndrome and the potential adverse effects of continuous neuromuscular blocking agent necessitates that these medications should be used judiciously with dose reduction in mind. The aims of the study were to improve the process of care by provider education of neuromuscular blocking agent titration and monitoring and to determine the impact of clinical endpoint based neuromuscular blocking agent titration protocol. Design:. We conducted a proof-of-concept historically controlled study of protocol-based intervention standardizing paralytic monitoring and titration using clinical variables. Education of the protocol was provided to ICU staff via bedside teaching and workshops. The primary outcomes were the time to reach goal paralysis and cumulative neuromuscular blocking agent dose. Secondary outcomes included maintenance of deeper sedation (Richmond Agitation and Sedation Scale –5) prior to neuromuscular blocking agent initiation, total time on mechanical ventilation, length of stay, and mortality. Setting:. Medical ICU at a quaternary academic hospital between March 2019 and June 2020. Patients:. Adult severe acute respiratory distress syndrome (Pao2/Fio2
- Published
- 2021
- Full Text
- View/download PDF